Dexcom (DXCM) Share-based Compensation (2010 - 2026)

Dexcom (DXCM) has reported Share-based Compensation for 17 consecutive years, with $39.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation fell 13.91% year-over-year to $39.0 million in Q2 2026; TTM through Jun 2026 was $162.4 million, a 2.29% decrease from a year earlier, with the FY2025 full-year figure at $159.6 million, down 6.34% from the prior year.
• Share-based Compensation was $39.0 million for Q2 2026 at Dexcom, down from $43.3 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $45.3 million in Q2 2025 and troughed at $29.1 million in Q1 2022.
• A 5-year average of $38.3 million and a median of $39.0 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation advanced 29.28% in 2022 and retreated 19.17% in 2025, its largest moves.
• Over 5 years, Share-based Compensation stood at $34.0 million in 2022, then grew by 8.53% to $36.9 million in 2023, then climbed by 17.34% to $43.3 million in 2024, then decreased by 19.17% to $35.0 million in 2025, then climbed by 11.43% to $39.0 million in 2026.
• The last three Share-based Compensation figures came in at $39.0 million (Q2 2026), $43.3 million (Q1 2026), and $35.0 million (Q4 2025), per Business Quant data.